<DOC>
	<DOCNO>NCT02104752</DOCNO>
	<brief_summary>The investigator propose test whether curcumin nanoparticles improve behavioral measure biomarkers cognition neuroplasticity patient schizophrenia already receive stable dose antipsychotic .</brief_summary>
	<brief_title>Curcumin Novel Treatment Improve Cognitive Dysfunction Schizophrenia</brief_title>
	<detailed_description>The investigator use formulation curcumin high bioavailability possess pharmacokinetic profile expect exert biological effect . Specifically , 36 subject enrol double-blind randomized control trial . They randomize curcumin placebo 8 week . At baseline , 4 8 week , subject receive assessment neurocognition ( e.g. , process speed , attention vigilance , work memory , learning , reason problem solve ) , social cognition , EEG biomarkers ( e.g. , visual cortical plasticity mismatch negativity ) , serum marker neurogenesis ( BDNF level ) , clinical symptom ( positive negative symptom ) . At week 2 6 subject return additional safety ( e.g. , vitals , side effect , akathisia ) medication adherence assessment . Improvement primary outcome measure ( MATRICS Consensus Cognitive Battery ) , well secondary outcome measure , compare participant randomize placebo versus curcumin . The result study establish whether curcumin viable adjunctive agent future large clinical trial .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>DSM5 diagnosis schizophrenia age 18 65 year understand spoken English sufficiently comprehend test procedure correct vision least 20/30 currently prescribe antipsychotic medication clinically significant neurological disease determine medical history ( e.g. , epilepsy ) history serious head injury ( i.e. , loss consciousness &gt; 1 hr. , neuropsychological sequela , cognitive rehabilitation post head injury ) sedatives benzodiazepine within 12 hrs test psychiatric hospitalization within 3 month prior study participation behavior suggest potential danger self others within 6 month prior study participation antipsychotic dose change 50 % 3 month prior study participation acute medical problem untreated chronic medical condition within 3 month prior study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Curcumin</keyword>
	<keyword>Turmeric</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Cognition</keyword>
	<keyword>Psychosis</keyword>
</DOC>